AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17194902 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (SCT)
Number of subjects: 106
Study 17194902 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 106
Study 15197210 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplement 1.09 g administered bid
Number of subjects: 421
Study 15197210 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA) liquid suspension 600 mg/d
Number of subjects: 421
Study 15197210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EPA and MA
Number of subjects: 421
Study 15197210 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 421
Study 15197210 — intervention group
Group type: COMPARATOR
Intervention: MA
Number of subjects: 421
Study 11520724 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal CPAP
Number of subjects: 48
Study 11520724 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 48
Study 11520724 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal CPAP after placebo
Number of subjects: 48
Study 11520724 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 48
Study 9781789 — intervention group
Group type: EXPERIMENTAL
Intervention: Erect exercise
Number of subjects: 19
Study 9781789 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine exercise
Number of subjects: 19
Study 8143399 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg felodipine ER
Number of subjects: 286
Study 8143399 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg felodipine ER
Number of subjects: 286
Study 8143399 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg felodipine ER
Number of subjects: 286
Study 8143399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 3278186 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-n1 (Wellferon) at a dose of 5 MU/m2 daily for 28 days and three times weekly for 5 months
Number of subjects: 66
Study 3278186 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 66
Study 31165350 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE)
Number of subjects: 28
Study 31165350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (E)
Number of subjects: 28
Study 31165350 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PE to E
Number of subjects: 28
Study 31165350 — intervention group
Group type: COMPARATOR
Intervention: Comparison of E to PE
Number of subjects: 28
Study 29569116 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity (HV) resistance training
Number of subjects: 53
Study 29569116 — intervention group
Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 53
Study 29569116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-velocity (LV) resistance training
Number of subjects: 53
Study 28526381 — intervention group
Group type: EXPERIMENTAL
Intervention: L-GSH supplementation
Number of subjects: 16
Study 28526381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25825328 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive anterior loading of the knee (5 sessions per week for 3 months)
Number of subjects: 22
Study 25825328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 22
Study 23731242 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 37
Study 23731242 — intervention group
Group type: COMPARATOR
Intervention: Control (non-activated laser/only photosensitizer)
Number of subjects: 37
Study 21596468 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (EG1) - 4 standard PE sessions/week
Number of subjects: 67
Study 21596468 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (EG2) - 4 high-intensity PE sessions/week
Number of subjects: 67
Study 21596468 — intervention group
Group type: COMPARATOR
Intervention: Control Group - standard PE (2 sessions/week)
Number of subjects: 67
Study 19885781 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 30
Study 19885781 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 30
Study 19885781 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (S+E)
Number of subjects: 30
Study 19885781 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 16456024 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 18
Study 15388303 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory and literacy measures
Number of subjects: 151
Study 15388303 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function measures
Number of subjects: 151
Study 15388303 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological loop and visual spatial sketchpad measures
Number of subjects: 151
Study 10761969 — intervention group
Group type: COMPARATOR
Intervention: Rarely/Never alcohol consumption
Number of subjects: 20951
Study 10761969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 3 drinks per month
Number of subjects: 20951
Study 10761969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 drink per week
Number of subjects: 20951
Study 10761969 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 to 4 drinks per week
Number of subjects: 20951
Study 10761969 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 to 6 drinks per week
Number of subjects: 20951
Study 10761969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or more drinks per day
Number of subjects: 20951
Study 9017724 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenetic music (2:8 time)
Number of subjects: 34
Study 9017724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mellow music (4:4 time)
Number of subjects: 34
Study 9017724 — intervention group
Group type: COMPARATOR
Intervention: White noise
Number of subjects: 34
Study 1503442 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (500 mg four times daily)
Number of subjects: 87
Study 1503442 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (gentamicin 80 mg every 8 h plus either cefuroxime 1,500 mg every 8 h or cephalothin 1,000 mg every 4 h)
Number of subjects: 87
Study 1503442 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 87
Study 1503442 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 87
Study 6722478 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy plus segmental gastrectomy
Number of subjects: 28
Study 6722478 — intervention group
Group type: COMPARATOR
Intervention: Proximal gastric vagotomy
Number of subjects: 28
Study 29098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 88
Study 29098353 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study 27788299 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk calculator
Number of subjects: 375
Study 27788299 — intervention group
Group type: COMPARATOR
Intervention: General OA risk information (Control)
Number of subjects: 375
Study 26241253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscular injection
Number of subjects: 67
Study 26241253 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline injection
Number of subjects: 67
Study 26241253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscular injection (Nulliparous participants)
Number of subjects: 67
Study 26241253 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline injection (Nulliparous participants)
Number of subjects: 67
Study 23764734 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) treatment in lean humans
Number of subjects: 0
Study 23764734 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) treatment in obese humans
Number of subjects: 0
Study 23764734 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) treatment in lean swine
Number of subjects: 0
Study 23764734 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) treatment in obese swine
Number of subjects: 0
Study 23764734 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 treatment
Number of subjects: 0
Study 20587585 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy
Number of subjects: 485
Study 20587585 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin injections (injection therapy)
Number of subjects: 485
Study 20587585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 485
Study 17641003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum magnesium levels
Number of subjects: 488
Study 17641003 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated hsCRP levels
Number of subjects: 488
Study 15665201 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scan within 5 days of injury
Number of subjects: 28
Study 15665201 — intervention group
Group type: COMPARATOR
Intervention: Usual management (control group)
Number of subjects: 28
Study 15665201 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scan
Number of subjects: 28
Study 12532161 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid plus hypocaloric diet for the first year and weight maintenance diet in year two
Number of subjects: 220
Study 10426245 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced schedule of six to seven antenatal visits
Number of subjects: 1117
Study 10426245 — intervention group
Group type: COMPARATOR
Intervention: Traditional schedule of 13 antenatal visits
Number of subjects: 1117
Study 9454228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer of larynx
Number of subjects: 49
Study 9454228 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant neoplasms of maxillo‐ethmoid complex
Number of subjects: 49
Study 9454228 — intervention group
Group type: COMPARATOR
Intervention: Healthy people
Number of subjects: 49
Study 1698446 — intervention group
Group type: EXPERIMENTAL
Intervention: MC903
Number of subjects: 20
Study 1698446 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 20
Study 1698446 — intervention group
Group type: EXPERIMENTAL
Intervention: MC903 and Betamethasone
Number of subjects: 20
Study 6449753 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide 1 mg
Number of subjects: 10
Study 6449753 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide 0.1 mg
Number of subjects: 10
Study 6449753 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 10
Study 30077419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional steroid (ILS) injection
Number of subjects: 29
Study 30077419 — intervention group
Group type: COMPARATOR
Intervention: Microlaryngeal surgery
Number of subjects: 29
Study 28832876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.4 mg/g nicotine content
Number of subjects: 169
Study 28832876 — intervention group
Group type: COMPARATOR
Intervention: Higher nicotine content cigarettes
Number of subjects: 169
Study 28832876 — intervention group
Group type: EXPERIMENTAL
Intervention: All nicotine doses
Number of subjects: 169
Study 28832876 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher nicotine doses
Number of subjects: 169
Study 26343274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight-control treatment strategy using the handscan (TCHS)
Number of subjects: 299
Study 26343274 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessments (TC)
Number of subjects: 299
Study 23582109 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-applied transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 52
Study 23582109 — intervention group
Group type: COMPARATOR
Intervention: Baclofen (10 mg twice daily, increasing to 25 mg over three weeks)
Number of subjects: 52
Study 23582109 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TENS vs Baclofen
Number of subjects: 52
Study 21223623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-care intervention (telephone and mail support)
Number of subjects: 118
Study 21223623 — intervention group
Group type: COMPARATOR
Intervention: Self-help group (control)
Number of subjects: 118
Study 21223623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-care intervention
Number of subjects: 118
Study 19146145 — intervention group
Group type: EXPERIMENTAL
Intervention: SybronEndo gauge
Number of subjects: 80
Study 19146145 — intervention group
Group type: EXPERIMENTAL
Intervention: Maillefer gauge
Number of subjects: 80
Study 17434899 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 70 mg/m² on day 2 plus oral estramustine 280 mg twice daily on days 1-5 (DE)
Number of subjects: 92
Study 17434899 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² on day 1 (D)
Number of subjects: 92
Study 12927020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate (1000 mg daily)
Number of subjects: 8
Study 12927020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11820041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intravenous insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg/dl)
Number of subjects: 1548
Study 11820041 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg/dl and maintenance of glucose at a level between 180 and 200 mg/dl)
Number of subjects: 1548
Study 9623009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ranitidine
Number of subjects: 10
Study 9623009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous famotidine
Number of subjects: 10
Study 9623009 — intervention group
Group type: COMPARATOR
Intervention: Control (no H2 blockers)
Number of subjects: 10
Study 9623009 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 10
Study 9174500 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education every 2 months by trained practice nurses for 1 year
Number of subjects: 1337
Study 9174500 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1337
Study 9174500 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 1337
Study 9174500 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 5 (sustaining desired changes in behavior)
Number of subjects: 1337
Study 2126746 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane-N2O anesthesia
Number of subjects: 100
Study 2126746 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-N2O anesthesia
Number of subjects: 100
Study 2126746 — intervention group
Group type: COMPARATOR
Intervention: Normocarbia (control)
Number of subjects: 100
Study 7023223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 50
Study 7023223 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 50
Study 7023223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside and Furosemide
Number of subjects: 50
Study 31026419 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal injection of tramadol
Number of subjects: 60
Study 31026419 — intervention group
Group type: COMPARATOR
Intervention: Saline solution injection (control)
Number of subjects: 60
Study 28417355 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 52
Study 28417355 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 52
Study 26515222 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable suture material (polyglycolic acid)
Number of subjects: 1126
Study 26515222 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable suture material (polypropylene)
Number of subjects: 1126
Study 23887449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 30
Study 23887449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Cytoflavin)
Number of subjects: 30
Study 20807460 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat from grass-fed animals
Number of subjects: 20
Study 20807460 — intervention group
Group type: COMPARATOR
Intervention: Red meat from concentrate-fed animals
Number of subjects: 20
Study 18537939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 272
Study 18537939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 17010738 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 147
Study 17010738 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg/week
Number of subjects: 147
Study 17010738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 12705296 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate placement of titanium dental implants (Im)
Number of subjects: 46
Study 12705296 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement of titanium dental implants (De)
Number of subjects: 46
Study 10944563 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril (1.5 mg/kg orally every eight hours)
Number of subjects: 135
Study 10944563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 8919720 — intervention group
Group type: EXPERIMENTAL
Intervention: UltramicroELISA method
Number of subjects: 100
Study 8919720 — intervention group
Group type: COMPARATOR
Intervention: Traditional biologic assay in mice
Number of subjects: 100
Study 1747268 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic patient education on cough
Number of subjects: 548
Study 1747268 — intervention group
Group type: COMPARATOR
Intervention: Control practices (matched control practices)
Number of subjects: 548
Study 7047173 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (mean dose 83 +/- 19 mg)
Number of subjects: 23
Study 7047173 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (same dose as above)
Number of subjects: 23
Study 7047173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31850777 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional buccal infiltration by metallic aspirating syringe
Number of subjects: 30
Study 31850777 — intervention group
Group type: COMPARATOR
Intervention: Buccal infiltration by computer‐controlled local anaesthetic device (Wand STA)
Number of subjects: 30
Study 28479217 — intervention group
Group type: EXPERIMENTAL
Intervention: DEF+TEST (200mg testosterone enanthate per week)
Number of subjects: 50
Study 28479217 — intervention group
Group type: COMPARATOR
Intervention: DEF (no testosterone)
Number of subjects: 50
Study 27454528 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (Photodynamic Therapy with curcumin and blue light)
Number of subjects: 24
Study 27454528 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT + S (Photodynamic Therapy with curcumin, surfactant SDS, and blue light)
Number of subjects: 24
Study 27454528 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhex (Chlorhexidine treatment)
Number of subjects: 24
Study 27454528 — intervention group
Group type: COMPARATOR
Intervention: PDT + S
Number of subjects: 24
Study 27454528 — intervention group
Group type: COMPARATOR
Intervention: Chlorhex
Number of subjects: 24
Study 24852116 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab (gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m² with cetuximab 500 mg/m²)
Number of subjects: 150
Study 24852116 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m²)
Number of subjects: 150
Study 22995673 — intervention group
Group type: EXPERIMENTAL
Intervention: LI85008F formulation (900 mg/day in three divided doses)
Number of subjects: 50
Study 22995673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three identical capsules)
Number of subjects: 50
Study 18710605 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulphate)
Number of subjects: 608
Study 18710605 — intervention group
Group type: COMPARATOR
Intervention: Normal salt (100% sodium chloride)
Number of subjects: 608
Study 17617307 — intervention group
Group type: EXPERIMENTAL
Intervention: DDT of the LAD < or = 600 milliseconds (group A)
Number of subjects: 24
Study 17617307 — intervention group
Group type: COMPARATOR
Intervention: DDT of the LAD > or = 600 milliseconds (group B)
Number of subjects: 24
Study 14983420 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral retro-resistance pressure (URP)
Number of subjects: 258
Study 14983420 — intervention group
Group type: COMPARATOR
Intervention: Multichannel urodynamics
Number of subjects: 258
Study 11607801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 8
Study 9699761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin and gentamicin
Number of subjects: 179
Study 9699761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin
Number of subjects: 179
Study 9699761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone
Number of subjects: 179
Study 9699761 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 179
Study 7794701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg twice daily
Number of subjects: 466
Study 7794701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at bedtime
Number of subjects: 466
Study 7794701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 2927449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy followed by breast irradiation
Number of subjects: 1843
Study 2927449 — intervention group
Group type: COMPARATOR
Intervention: Total mastectomy
Number of subjects: 1843
Study 2927449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy with irradiation
Number of subjects: 1843
Study 2927449 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy without irradiation
Number of subjects: 1843
Study 2927449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy with radiation and adjuvant chemotherapy
Number of subjects: 1843
Study 2927449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy (with or without irradiation)
Number of subjects: 1843